136 related articles for article (PubMed ID: 31917068)
1. Long-term metabolic and cardiovascular effects of antipsychotic drugs. A meta-analysis of randomized controlled trials.
Rotella F; Cassioli E; Calderani E; Lazzeretti L; Ragghianti B; Ricca V; Mannucci E
Eur Neuropsychopharmacol; 2020 Mar; 32():56-65. PubMed ID: 31917068
[TBL] [Abstract][Full Text] [Related]
2. [Drawing up guidelines for the attendance of physical health of patients with severe mental illness].
Saravane D; Feve B; Frances Y; Corruble E; Lancon C; Chanson P; Maison P; Terra JL; Azorin JM;
Encephale; 2009 Sep; 35(4):330-9. PubMed ID: 19748369
[TBL] [Abstract][Full Text] [Related]
3. [Antipsychotics in bipolar disorders].
Vacheron-Trystram MN; Braitman A; Cheref S; Auffray L
Encephale; 2004; 30(5):417-24. PubMed ID: 15627046
[TBL] [Abstract][Full Text] [Related]
4. Tolerability and Safety Profile of Cariprazine in Treating Psychotic Disorders, Bipolar Disorder and Major Depressive Disorder: A Systematic Review with Meta-Analysis of Randomized Controlled Trials.
Lao KS; He Y; Wong IC; Besag FM; Chan EW
CNS Drugs; 2016 Nov; 30(11):1043-1054. PubMed ID: 27550371
[TBL] [Abstract][Full Text] [Related]
5. Mortality Risk Associated With Long-acting Injectable Antipsychotics: A Systematic Review and Meta-analyses of Randomized Controlled Trials.
Kishi T; Matsunaga S; Iwata N
Schizophr Bull; 2016 Nov; 42(6):1438-1445. PubMed ID: 27086079
[TBL] [Abstract][Full Text] [Related]
6. Atypical antipsychotics for psychosis in adolescents.
Kumar A; Datta SS; Wright SD; Furtado VA; Russell PS
Cochrane Database Syst Rev; 2013 Oct; (10):CD009582. PubMed ID: 24129841
[TBL] [Abstract][Full Text] [Related]
7. Tolerability of atypical antipsychotics in the treatment of adults with schizophrenia or bipolar disorder: a mixed treatment comparison of randomized controlled trials.
Edwards SJ; Smith CJ
Clin Ther; 2009 Jun; 31 Pt 1():1345-59. PubMed ID: 19698898
[TBL] [Abstract][Full Text] [Related]
8. Efficacy, Acceptability, and Tolerability of Antipsychotics in Treatment-Resistant Schizophrenia: A Network Meta-analysis.
Samara MT; Dold M; Gianatsi M; Nikolakopoulou A; Helfer B; Salanti G; Leucht S
JAMA Psychiatry; 2016 Mar; 73(3):199-210. PubMed ID: 26842482
[TBL] [Abstract][Full Text] [Related]
9. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.
Krzystanek M; Krupka-Matuszczyk I
Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416
[TBL] [Abstract][Full Text] [Related]
10. Asenapine for schizophrenia and bipolar disorder: a review of the efficacy and safety profile for this newly approved sublingually absorbed second-generation antipsychotic.
Citrome L
Int J Clin Pract; 2009 Dec; 63(12):1762-84. PubMed ID: 19840150
[TBL] [Abstract][Full Text] [Related]
11. Second-generation antipsychotic drugs and short-term mortality: a systematic review and meta-analysis of placebo-controlled randomised controlled trials.
Schneider-Thoma J; Efthimiou O; Huhn M; Krause M; Reichelt L; Röder H; Davis JM; Salanti G; Leucht S
Lancet Psychiatry; 2018 Aug; 5(8):653-663. PubMed ID: 30042077
[TBL] [Abstract][Full Text] [Related]
12. Equally increased risk for metabolic syndrome in patients with bipolar disorder and schizophrenia treated with second-generation antipsychotics.
Correll CU; Frederickson AM; Kane JM; Manu P
Bipolar Disord; 2008 Nov; 10(7):788-97. PubMed ID: 19032710
[TBL] [Abstract][Full Text] [Related]
13. Medication-Induced Akathisia with Newly Approved Antipsychotics in Patients with a Severe Mental Illness: A Systematic Review and Meta-Analysis.
Demyttenaere K; Detraux J; Racagni G; Vansteelandt K
CNS Drugs; 2019 Jun; 33(6):549-566. PubMed ID: 31065941
[TBL] [Abstract][Full Text] [Related]
14. Second-generation antipsychotic long-acting injections in bipolar disorder: Systematic review and meta-analysis.
Prajapati AR; Wilson J; Song F; Maidment I
Bipolar Disord; 2018 Dec; 20(8):687-696. PubMed ID: 30417552
[TBL] [Abstract][Full Text] [Related]
15. Quetiapine versus other atypical antipsychotics for schizophrenia.
Asmal L; Flegar SJ; Wang J; Rummel-Kluge C; Komossa K; Leucht S
Cochrane Database Syst Rev; 2013 Nov; (11):CD006625. PubMed ID: 24249315
[TBL] [Abstract][Full Text] [Related]
16. Paliperidone palmitate for schizophrenia.
Nussbaum AM; Stroup TS
Cochrane Database Syst Rev; 2012 Jun; (6):CD008296. PubMed ID: 22696377
[TBL] [Abstract][Full Text] [Related]
17. Metabolic syndrome and metabolic abnormalities in bipolar disorder: a meta-analysis of prevalence rates and moderators.
Vancampfort D; Vansteelandt K; Correll CU; Mitchell AJ; De Herdt A; Sienaert P; Probst M; De Hert M
Am J Psychiatry; 2013 Mar; 170(3):265-74. PubMed ID: 23361837
[TBL] [Abstract][Full Text] [Related]
18. Obesity and related metabolic abnormalities during antipsychotic drug administration: mechanisms, management and research perspectives.
Baptista T; Kin NM; Beaulieu S; de Baptista EA
Pharmacopsychiatry; 2002 Nov; 35(6):205-19. PubMed ID: 12518268
[TBL] [Abstract][Full Text] [Related]
19. Asenapine: a clinical review of a second-generation antipsychotic.
Stoner SC; Pace HA
Clin Ther; 2012 May; 34(5):1023-40. PubMed ID: 22494521
[TBL] [Abstract][Full Text] [Related]
20. Aripiprazole for the maintenance treatment of bipolar I disorder: A review.
McIntyre RS
Clin Ther; 2010; 32 Suppl 1():S32-8. PubMed ID: 20152551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
